Novartis bone marrow cancer drug meets goal in late-stage study
ZURICH Dec 6 (Reuters) - Swiss drugmaker Novartis said on Friday its experimental drug LBH589 for a type of bone marrow cancer had met its primary goal in a late-stage study.
The Phase III study found LBH589 in combination with bortezomib and dexamethasone significantly extended survival in patients with relapsed or relapsed and refractory multiple myeloma without their disease worsening, the drugmaker said.
Multiple myeloma is a type of bone marrow cancer that affects approximately 1 to 5 in every 100,000 people worldwide each year.
- Investigators look for motive in Malaysia plane disappearance |
- Malaysian PM says lost airliner was diverted deliberately |
- Police make third arrest in murder of Colorado socialite
- Democrats seek ways to limit Obamacare fallout after Florida defeat
- Indian Ocean poses daunting challenge in search for missing Malaysia plane